Daniel had purulent rhinorrhea with facial pain and headache. His condition was giving him a bad experience.
Help turn it into a Good experience

IDSA 2012 Diagnosis: The following three clinical presentations are important in differentiating bacterial from viral rhinosinusitis:²

Persistent symptoms
≥10 days with no improvement

Severe symptoms
high fever of at least 39°C (102°F) and purulent nasal discharge or facial pain for at least 3–4 consecutive days at the beginning of illness

Double sickening
worsening symptoms, characterized by typical viral upper respiratory infection symptoms that appear to improve, followed by the new onset of worsening symptoms after 5–6 days

Treatment of ABRS: Commence symptom management including analgesics and antipyretics. Antibiotic treatment should be started empirically.

IDSA: Infectious Diseases Society of America.
ABRS: Acute bacterial rhinosinusitis.

Augmentin® 875 mg Tablets
Amoxicillin as trihydrate 875 mg
Clavulanic Acid as potassium salt 125 mg
Pharmacokinetics

Overall mean concentrations of both amoxicillin and clavulanate at different sinonasal sites


In the treatment of ABRS, Augmentin® has experience that counts

**ABRS**: Acute bacterial rhinosinusitis

**Augmentin® 875 mg Tablets**

Amoxicillin as trihydrate 875 mg
Clavulanic Acid as potassium salt 125 mg
Results of the Survey of Antibiotic Resistance

Susceptibility trends
of Amoxicillin clavulanate in *S. pneumoniae*

- **Ukraine**
  - CLSI (%): 100 | 100

- **Lebanon**
  - CLSI (%): 96.5 | 96.5

- **Pakistan**
  - CLSI (%): 100 | 100

- **China**
  - CLSI (%): 89.2 | 89.2 (2009-11)
  - CLSI (%): 75 | 75 (2013-14)

- **Turkey**
  - CLSI (%): 91.3 | 91.3

- **Senegal**
  - CLSI (%): 100 | 100

- **Ivory Coast**
  - CLSI (%): 100 | 100

- **Kenya**
  - CLSI (%): 95.2 | 95.2

- **Bahrain**
  - CLSI (%): 98 | 98

- **India**
  - CLSI (%): 91.8 | 91.8

- **Thailand**
  - CLSI (%): 97.1 | 97.1

- **Vietnam**
  - CLSI (%): 76.1 | 76.1

- **Singapore**
  - CLSI (%): 94.8 | 94.8

- **UAE**
  - CLSI (%): 87.5 | 87.5

**CLSI:** Clinical & Laboratory Standards Institute.

#Disclaimer: Susceptibility trends vary with time and geography. Kindly refer to local surveillance data before prescribing.

† Isolates were collected from various samples like sputum, tracheo-bronchial aspirate, bronchoalveolar lavage, sinus, middle ear effusion, blood, nasopharyngeal aspirate or pleural fluid.

* Rates of resistance in different countries were determined over different time periods.

**Augmentin® 875 mg Tablets**
Amoxicillin as trihydrate 875 mg
Clavulanic Acid as potassium salt 125 mg
Amoxicillin clavulanate is

- Recommended as empiric therapy
- Recommended over a respiratory fluoroquinolone

Macrolides (clarithromycin and azithromycin) are not recommended for empiric therapy due to high rates of resistance among S. pneumoniae.

*Quality of evidence-Weak, Strength of recommendation-low
†Quality of evidence-Weak, Strength of recommendation-moderate
‡ Quality of evidence -Strong, Strength of recommendation-moderate

IDSA: Infectious Diseases Society of America.
ABRS: Acute bacterial rhinosinusitis.

Augmentin® 875 mg Tablets
Amoxicillin as trihydrate 875 mg
Clavulanic Acid as potassium salt 125 mg
Summary

Sinusitis adversely affects quality of life and may lead to complications\(^1\)

Differentiating between Viral and Bacterial sinusitis is key to appropriate management\(^2\)

Amoxicillin - clavulanate:

- Favourable PK/PD parameters\(^3\)
- Supported by global surveillance data\(^6a-6h\)
- Recommended as empiric therapy by IDSA 2012, in treating ABRS over cephalosporins, macrolides and fluoroquinolones\(^2\)

Augmentin\(^\circledast\) 875 mg Tablets
Amoxicillin as trihydrate 875 mg
Clavulanic Acid as potassium salt 125 mg
Dosage and Administration

Main Safety Information:
Contraindicated in patients with known hypersensitivity to β-lactam antibiotics (penicillins & cephalosporins).
Gastrointestinal disturbances are common.
Prolonged use may result in overgrowth of non-susceptible organisms.

Augmentin®
875 mg tablet

Adults and children (≥40 kg)

Standard dose
ONE AUGMENTIN® 875 mg/125 mg two times a day

Higher dose
ONE AUGMENTIN® 875 mg/125 mg three times a day

Augmentin® 875 mg Tablets
Amoxicillin as trihydrate 875 mg
Clavulanic Acid as potassium salt 125 mg
References


7. Augmentin MOH approved Prescribing Information.

Augmentin® 875 mg Tablets
Amoxicillin as trihydrate 875 mg
Clavulanic Acid as potassium salt 125 mg
Augmentin® 875 mg Tablets
Amoxicillin as trihydrate 875 mg
Clavulanic Acid as potassium salt 125 mg